Britain and America have announced a significant trade agreement that will ensure no import taxes on UK drug exports going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the public health system. This commitment secures that duties on these key products will remain at zero for a duration of three years.
This agreement comes after previous warnings to dramatically increase tariffs on branded pharmaceutical imports, with figures discussed up to double the cost.
"This deal with the United Kingdom bolsters the global environment for innovative medicines and introduces long-overdue fairness to transatlantic medicine commerce," a statement noted.
Commercial Importance
Drugs represent one of the Britain's largest export categories to the United States, which is easily the primary market for major UK drugmakers.
Trade data reveal that in the one-year period leading up to September, the UK exported drugs worth over eleven billion pounds to the US. This figure made up 17.4% of all goods exports in that span.
"This guarantee safeguards work, stimulates capital expenditure and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The pact entails several key changes from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be capped at 15%. Previously, refunds topped twenty percent.
Broader Context
The pact comes amid a protracted dispute between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were intensified by arguments that American customers were charged significantly more for the same drugs than consumers in the UK and Europe.
Recently, several significant drug company projects in the UK have been paused or scrapped, while major funding commitments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its resources over the last ten years.
